Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects, aged 18 - 30 years~* Signed informed consent after being advised of the risks and benefits of the study in a language able to understand, and prior to performance of any study specific procedure.~* Free of obvious health problems with acceptable medical history by screening evaluation and physical examination.~* Subject of not of child-bearing potential or all of the following: A urine/serum ß-HCG pregnancy test gives a negative result, use of adequate contraceptive precautions for 30 days before first vaccination.~Exclusion Criteria:~* Known or suspected history of smallpox vaccination or typical vaccinia scar.~* Positive test result in MVA specific ELISA or PRNT at screening.~* Positive result in HIV or HCV antibody test at screening.~* HbsAG positive at screening.~* Pregnancy or breast-feeding.~* Uncontrolled serious infection i.e. not responding to antimicrobial therapy~* History of any serious medical condition, which in the opinion of the investigator, would compromise the safety of the subject.~* History of autoimmune disease~* History of malignancy.~* History of chronic alcohol abuse and/or intravenous drug abuse.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of anaphylaxis or severe allergic reaction.~* Acute disease (a moderate or severe illness with or without a fever) at the time of enrolment.~* Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion.~* Chronic administration of immuno-suppressants or other immune-modifying drugs.~* Administration or planned administration of immunoglobulins and/or any blood products during the study period.~* Use of any investigational or non-registered drug or vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
- Group 2 (Type: ACTIVE_COMPARATOR): healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
- Group 3 (Type: ACTIVE_COMPARATOR): healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous

Based on this trial design, predict the completion outcome and termination type (if applicable).